A different treatment strategy for LQTS caused by loss-of-function mutations in the KV7.1+KCNE1 channel would be to pharmacologically augment the KV7.1+KCNE1 channel function of these LQTS mutants, thereby shortening the prolonged QT interval and lower the risk of arrhythmia development. Here, KCNQ1 is linked to cardiac arrhythmia.